HCMA RECOGNIZED CENTER OF EXCELLENCE
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

HCMA RECOGNIZED CENTER OF EXCELLENCE Trademark

Serial Number: 50136154

HCMA RECOGNIZED CENTER OF EXCELLENCE is a trademark filed by HYPERTROPHIC CARDIOMYOPATHY ASSOCIATION on September 29, 2026. The trademark is classified under Class 16 (Paper Goods), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

HYPERTROPHIC CARDIOMYOPATHY ASSOCIATION (4 trademarks)

66 Ford Road
Denville, NJ 07834

Entity Type: 54

Trademark Details

Filing Date

September 29, 2026

Registration Date

Not Registered

Goods & Services

Promoting public awareness of hypertrophic cardiomyopathy and other thick-hearted disorders including Danon disease, Fabry disease, cardiac amyloidosis, Pompe disease, Friedrich’s ataxia, RASopathies, PRKAG2, mitochondrial diseases, and cardiac sarcoidosis; Promoting public interest and awareness of hypertrophic cardiomyopathy and other thick-hearted disorders including Danon disease, Fabry disease, cardiac amyloidosis, Pompe disease, Friedrich’s ataxia, RASopathies, PRKAG2, mitochondrial diseases, and cardiac sarcoidosis; Charitable services, namely, promoting public awareness of hypertrophic cardiomyopathy and other thick-hearted disorders including Danon disease, Fabry disease, cardiac amyloidosis, Pompe disease, Friedrich’s ataxia, RASopathies, PRKAG2, mitochondrial diseases, and cardiac sarcoidosis; Arranging and conducting of volunteer programs and community service projects for charitable purposes; Promoting collaboration within the scientific, research and provider communities to achieve advances in the field of hypertrophic cardiomyopathy and other thick-hearted disorders including Danon disease, Fabry disease, cardiac amyloidosis, Pompe disease, Friedrich’s ataxia, RASopathies, PRKAG2, mitochondrial diseases, and cardiac sarcoidosis

Printed educational course materials in the field of hypertrophic cardiomyopathy and other thick-hearted disorders including Danon disease, Fabry disease, cardiac amyloidosis, Pompe disease, Friedrich’s ataxia, RASopathies, PRKAG2, mitochondrial diseases, and cardiac sarcoidosis; Printed magazine columns about hypertrophic cardiomyopathy and other thick-hearted disorders including Danon disease, Fabry disease, cardiac amyloidosis, Pompe disease, Friedrich’s ataxia, RASopathies, PRKAG2, mitochondrial diseases, and cardiac sarcoidosis; Printed general feature magazines in the field of hypertrophic cardiomyopathy and other thick-hearted disorders including Danon disease, Fabry disease, cardiac amyloidosis, Pompe disease, Friedrich’s ataxia, RASopathies, PRKAG2, mitochondrial diseases, and cardiac sarcoidosis; Printed magazines in the field of hypertrophic cardiomyopathy and other thick-hearted disorders including Danon disease, Fabry disease, cardiac amyloidosis, Pompe disease, Friedrich’s ataxia, RASopathies, PRKAG2, mitochondrial diseases, and cardiac sarcoidosis; Printed materials, namely, journals featuring hypertrophic cardiomyopathy and other thick-hearted disorders including Danon disease, Fabry disease, cardiac amyloidosis, Pompe disease, Friedrich’s ataxia, RASopathies, PRKAG2, mitochondrial diseases, and cardiac sarcoidosis; Printed journals in the field of hypertrophic cardiomyopathy and other thick-hearted disorders including Danon disease, Fabry disease, cardiac amyloidosis, Pompe disease, Friedrich’s ataxia, RASopathies, PRKAG2, mitochondrial diseases, and cardiac sarcoidosis; Printed informational flyers featuring hypertrophic cardiomyopathy and other thick-hearted disorders including Danon disease, Fabry disease, cardiac amyloidosis, Pompe disease, Friedrich’s ataxia, RASopathies, PRKAG2, mitochondrial diseases, and cardiac sarcoidosis; Printed diagrams for hypertrophic cardiomyopathy and other thick-hearted disorders including Danon disease, Fabry disease, cardiac amyloidosis, Pompe disease, Friedrich’s ataxia, RASopathies, PRKAG2, mitochondrial diseases, and cardiac sarcoidosis

Filing History

APPLICATION FILING RECEIPT MAILED
Sep 29, 2026 MAFR
NEW APPLICATION ENTERED
Sep 29, 2026 NWAP